Tharimmune to Present at the Microcap Conference 2025
-
Trapped, starving and afraid in besieged Sudan city
-
Showdown looms as EU-Mercosur deal nears finish line
-
Messi mania peaks in India's pollution-hit capital
-
Wales captains Morgan and Lake sign for Gloucester
-
Serbian minister indicted over Kushner-linked hotel plan
-
Eurovision 2026 will feature 35 countries: organisers
-
Cambodia says Thailand bombs province home to Angkor temples
-
US-Ukrainian talks resume in Berlin with territorial stakes unresolved
-
Small firms join charge to boost Europe's weapon supplies
-
Driver behind Liverpool football parade 'horror' warned of long jail term
-
German shipyard, rescued by the state, gets mega deal
-
Flash flood kills dozens in Morocco town
-
'We are angry': Louvre Museum closed as workers strike
-
Australia to toughen gun laws as it mourns deadly Bondi attack
-
Stocks diverge ahead of central bank calls, US data
-
Wales captain Morgan to join Gloucester
-
UK pop star Cliff Richard reveals prostate cancer treatment
-
Mariah Carey to headline Winter Olympics opening ceremony
-
Indonesia to revoke 22 forestry permits after deadly floods
-
Louvre Museum closed as workers strike
-
Spain fines Airbnb 64 mn euros for posting banned properties
-
Japan's only two pandas to be sent back to China
-
Zelensky, US envoys to push on with Ukraine talks in Berlin
-
Australia to toughen gun laws after deadly Bondi shootings
-
Lyon poised to bounce back after surprise Brisbane omission
-
Australia defends record on antisemitism after Bondi Beach attack
-
US police probe deaths of director Rob Reiner, wife as 'apparent homicide'
-
'Terrified' Sydney man misidentified as Bondi shooter
-
Cambodia says Thai air strikes hit home province of heritage temples
-
EU-Mercosur trade deal faces bumpy ride to finish line
-
Inside the mind of Tolkien illustrator John Howe
-
Mbeumo faces double Cameroon challenge at AFCON
-
Tongue replaces Atkinson in only England change for third Ashes Test
-
England's Brook vows to rein it in after 'shocking' Ashes shots
-
Bondi Beach gunmen had possible Islamic State links, says ABC
-
Lakers fend off Suns fightback, Hawks edge Sixers
-
Louvre trade unions to launch rolling strike
-
Far-right Kast wins Chile election landslide
-
Asian markets drop with Wall St as tech fears revive
-
North Korean leader's sister sports Chinese foldable phone
-
Iran's women bikers take the road despite legal, social obstacles
-
Civilians venture home after militia seizes DR Congo town
-
Countdown to disclosure: Epstein deadline tests US transparency
-
Desperate England looking for Ashes miracle in Adelaide
-
Far-right Kast wins Chile election in landslide
-
What we know about Australia's Bondi Beach attack
-
Witnesses tell of courage, panic in wake of Bondi Beach shootings
-
Chiefs out of playoffs after decade as Mahomes hurts knee
-
Chilean hard right victory stirs memories of dictatorship
-
Volunteers patrol Thai villages as artillery rains at Cambodia border
NYSE - LSE
Tharimmune to Present at the Microcap Conference 2025
BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.
Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.
Event: The Microcap Conference 2025
Location: Studio 4, Borgata Hotel Casino & Spa
Date: Thursday January 30, 2025
Time: 10:00 AM Eastern Time
Investors interested in meeting with management can register for the conference here.
About Tharimmune
Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to treating autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. For more information, please visit: www.tharimmune.com.
Contacts
Tharimmune, Inc.
[email protected]
Alliance Advisors IR
Tirth T. Patel
[email protected]
212-201-6614
Contact Information
Tirth Patel
Alliance Advisors IR
[email protected]
1-212-201-6614
SOURCE: Tharimmune Inc.
View the original press release on ACCESS Newswire
M.A.Colin--AMWN
